This review is intended as an educational resource for healthcare professionals who encounter patients with adverse reactions while receiving immune checkpoint inhibitor therapy for cancer. It summarises the impact, diagnosis, and management of gastrointestinal and endocrine immune-related adverse reactions (irARs) in these patients, using current clinical consensus. The review also presents and discusses two case studies of common gastrointestinal and endocrine irARs.This publication has been created with an unrestricted educational grant from MSD, AstraZeneca and Roche. The content is entirely independent and based on published studies and the author’s opinion.
Please login below to download this issue (PDF)